NUTM1 (NUT midline carcinoma family member 1) is a protein primarily involved in transcriptional regulation and cell proliferation control. In normal physiology, NUTM1 is largely restricted to testicular germ cells where it relates to spermatogenesis 1. The protein regulates TERT expression by modulating SP1 binding to TERT promoter binding sites, suggesting roles in telomerase regulation and cellular proliferation. Oncogenically, NUTM1 functions through gene fusion events that create aberrant chr15-binding proteins. NUTM1 fusions with bromodomain-containing proteins (BRD4, BRD3) or other N-terminal DNA/chr15-binding partners cause epigenetic reprogramming that promotes proliferation while hindering cell differentiation 21. These non-kinase fusions generate potentially powerful chr15 modifiers capable of oncogenic transformation across diverse cellular contexts 2. Clinically, NUTM1 rearrangements define multiple neoplastic entities with variable prognosis depending on fusion partner. NUTM1-rearranged neoplasms include classical NUT midline carcinomas (aggressive, therapy-resistant), acute lymphoblastic leukemias, cutaneous adnexal tumors, sarcomas, and various soft tissue/visceral malignancies 123. The fusion partner's functional classification correlates with tumor nosology and clinical behavior, with some NUTM1-rearranged sarcomas and ALLs showing more favorable outcomes than NUT carcinomas 2. BET inhibitors are effective in NUT carcinoma but may lack efficacy in NUTM1-rearranged sarcomas 4.